Genetic Predisposition Environmental Factors Obesity TYPE 2 DIABETES

Slides:



Advertisements
Similar presentations
Chapter 20 Essential Concepts in Molecular Pathology Companion site for Molecular Pathology Author: William B. Coleman and Gregory J. Tsongalis.
Advertisements

Clinical Presentation of Type 2 Diabetes 1. Risk Factors for Prediabetes and Type 2 Diabetes Family history of diabetes mellitus Cardiovascular disease.
Sex Differences in Overweight & Obesity.
Endocrine Diseases Dr/Abd Elghany Hefnawy T3&T4 PTH Anterior Posterior PAO Insulin Glucagon Adrenalin,Noradrenalin Corticosteriods.
Diabetes Mellitus (“sweet urine”) : Metabolic disorder characterized by high blood sugar (glucose) levels resulting from defects in insulin secretion or.
Pancreatic Hormones Glucagon Insulin.
Medical University Graz Clinic of Obstetrics and Gynaecology, Medical University of Graz, Austria Gernot Desoye Intrauterine Hyperinsulinemia as Major.
Homeostatic Control of Metabolism
Goals: 1) Understand the mechanism for ↑LDL in Type II diabetes 2) Having previously established the link between endothelial cell damage (loss of inhibitory.
Metabolic effects of Insulin and Glucagon Metabolism in the Well fed state Metabolism in the Starvation and Diabetes Mellitus Integration of Metabolism.
Diabetes Mellitus (Lecture 2). Type 2 DM 90% of diabetics (in USA) Develops gradually may be without obvious symptoms may be detected by routine screening.
THE SABBATICAL DIET WEIGHT LOSS PROGRAM
By Hussam A.S. Murad and Khaled A. Mahmoud Department of Pharmacology and Therapeutics Faculty of Medicine, Ain Shams University By Hussam A.S. Murad.
The pathophysiology of type 2 diabetes Jean GIRARD Institut Cochin Paris.
Regulating Blood Sugar Islets of Langerhans groups of cells in the pancreas beta cells produce insulin alpha cells produce glucagon.
Part 8. Rationale for SGLT2 Inhibitors Inhibit glucose reabsorption in the renal proximal tubule Resultant glucosuria leads to a decline in plasma glucose.
Rapid in vivo Effects of Pioglitazone on Adipose Tissue Gene Expression and Insulin Action in Humans with Type 2 Diabetes Mellitus(T2DM) P. Kishore, W.J.
Part 7. GLUT2 AMG Uptake NGTT2DMNGTT2DM AMG=methyl-  -D-[U 14 C]-glucopyranoside; CPM=counts per minute. Rahmoune H, et al. Diabetes. 2005;54:
Regulation of Blood Sugar Level at the Whole Animal Owen M c Guinness January 11, 2010 Course: MPB 333 Contact info: Phone: Office: 831C Light.
IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.
Identify the risk factors, diagnosis and prevalence of diabetes in the United States. Describe the function of the pancreas, the intestines and liver.
Diabetes Mellitus Type 2
Part 4.
Alterations of Lipid Metabolism in Diabetes Mellitus
Diet Study for Nonalcoholic Fatty Liver Disease Lab meeting.
Diabetes Mellitus Classification & Pathophysiology.
 Insulin is a peptide hormone released by beta cells when glucose concentrations exceed normal levels (70–110 mg/dL).  The effects of insulin on its.
Diabetes Mellitus Part 1 Kathy Martin DNP, RN, CNE.
TEMPLATE DESIGN © CONTINUOUS GLUCOSE MONITORING, ORAL GLUCOSE TOLERANCE, AND INSULIN – GLUCOSE PARAMETERS IN ADOLESCENTS.
Metabolic Syndrome Endocrine Block 1 Lecture Dr. Usman Ghani.
Part 5. Insulin Resistance and  -Cell Dysfunction: Summary Individuals with impaired glucose tolerance –Are maximally or near-maximally insulin resistant.
Endocrine Block 1 Lecture Dr. Usman Ghani
Endocrine Block Dr. Usman Ghani
Hematopoietic Tissue Factor–Protease-Activated Receptor 2 Signaling Promotes Hepatic Inflammation and Contributes to Pathways of Gluconeogenesis and Steatosis.
By Dr. Sumbul Fatma Clinical Chemistry Unit Department of Pathology
Growth Hormone Prof. K. Sivapalan.
Endocrine Block 1 Lecture Dr. Usman Ghani
Figure 2 Pathophysiology of hyperglycaemia in T2DM
המשותף לכל סוגי הסוכרת היפרגליקמיה כרונית.
REVIEW SLIDES.
Diet, Obesity, and Chronic Disease
Volume 22, Issue 8, Pages (February 2018)
White adipose tissue (HFD)
Adipose tissue and reproduction in women
THE ENDOCANNABINOID SYSTEM AND CARDIOMETABOLIC RISK
Ludger Scheja, Joerg Heeren  Journal of Hepatology 
Grzegorz Sumara, Olga Sumara, Jason K. Kim, Gerard Karsenty 
Volume 74, Issue 7, Pages (October 2008)
Relationship between plasma glucose, insulin and glucagon levels
Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk  Jennifer H. Stern, Joseph M. Rutkowski,
Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Prediabetes in youths: mechanisms and biomarkers
DIABETES MELLITUS. DIABETES MELLITUS It is a syndrome of impaired carbohydrate, protein and fat metabolism caused by either lack of insulin secretion.
Body weight and oral glucose tolerance in diet-induced obese rats at 5 weeks post-surgery. Body weight and oral glucose tolerance in diet-induced obese.
The Stunned β Cell: A Brief History
Volume 16, Issue 11, Pages (November 2008)
“De-liver-ance” From CB1: A Way to Counteract Insulin Resistance?
A whole body model for both glucose and fatty acid metabolism
Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Volume 23, Issue 6, Pages (June 2016)
Volume 1, Issue 1, Pages (January 2005)
Volume 1, Issue 4, Pages (April 2005)
Identification of SH2-B as a key regulator of leptin sensitivity, energy balance, and body weight in mice  Decheng Ren, Minghua Li, Chaojun Duan, Liangyou.
H.N. Ginsberg, W.V. Brown. Arterioscler Thromb Vasc Biol 2011;31:
a b c d OGTT OGTT *** ** * * Blood glucose (mg/dL) AUC (mg/dL/min) ND
Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.
Transgenic restoration of long-chain n-3 PUFA protects against obesity-linked insulin resistance and glucose intolerance. Transgenic restoration of long-chain.
The underlying physiological basis of the HOMA model.
Effects of Rosi treatment on ASKO mice.
Presentation transcript:

Genetic Predisposition Environmental Factors Obesity TYPE 2 DIABETES Normal -cells Defective -cells Insulin Resistance Hyperinsulinemia with Normal Glucose Tolerance Impaired Glucose Tolerance ≥ 65% -cell defect TYPE 2 DIABETES Figure A1.

Insulin sensitivity (SI) Minimal Model Glucose levels Insulin sensitivity (SI) Β-cell response Insulin levels Insulin injection Glucose injection Figure A2.

Figure A3.

Week 0 Week 2 Week 4 Secretion Week 6 Insulin Sensitivity 2500 2000 1500 Week 6 Secretion 1000 500 1 2 3 4 5 6 7 8 Insulin Sensitivity Figure A4.

Cause of Hyperinsulinemia? Conventional wisdom: Insulin Resistance Figure A4 Figure A5 Cause of Hyperinsulinemia? Conventional wisdom: Increased fasting glycemia and/or impaired glucose tolerance Hyperinsulinemia (Increased secretion, Reduced clearance) Figure A5.

Insulin GLP-1 Glucose GH FFA Cortisol BASELINE 6 WKS FAT FEEDING 300 9.0 * * Insulin * 200 6.0 pM pM 100 * * 3.0 * GLP-1 * 0.0 125 4.0 Glucose mg/dL ng/mL 100 * 2.0 GH 75 0.0 8.0 1.0 * FFA * * * * * * * * * * 0.8 6.0 Cortisol * * 0.6 * μg/mL mM 4.0 * 0.4 2.0 0.2 0.0 0.0 6am 9 12pm 3 6pm 9 12am 3 6am 6am 9 12pm 3 6pm 9 12am 3 6am Figure A6.

AND INTERSTITIAL FLUID INSULIN IN PLASMA AND INTERSTITIAL FLUID Hand-in-glove relationship between interstitial insulin and glucose disposal Plasma Lymph Insulin Levels Glucose Uptake 2 4 6 10 60 240 360 Time (minutes) 120 180 300 8 Lymph Insulin (uU/ml) 20 30 50 40 Rd Glucose disposal Figure A7.

Plasma Interstitial fluid Glucose uptake into cells Insulin injection INSULIN [μU/ml] Plasma INSULIN [μU/ml] Interstitial fluid Glucose uptake into cells GLUCOSE DISPOSAL [mg/kg per min] Figure A8.

Glucose Flux (mg/min per kg) Glucose Flux (mg/min per kg) 4 8 12 16 UPTAKE 30 60 90 120 150 180 INSULIN 3.33 mU/min per kg Glucose Flux (mg/min per kg) Time (minutes) 30 60 90 120 150 180 -1 1 2 3 4 Glucose Flux (mg/min per kg) Time (minutes) LIVER OUTPUT INSULIN 3.33 mU/min per kg HGO NHGO Rd Figure A9.

Figure A10.

Transendothelial transport barrier Insulin FFA adipocytes GLUCOSE PRODUCTION Figure A11.

Week 0 Week 6 Dog 1 Dog 2 Dog 3 Dog 4 35 Week 0 Week 6 * * * * * * 30 Dog 1 Body Weight (kg) 25 Dog 2 20 -2 2 4 6 Weeks on diet 1000 * Dog 3 750 +110% Body Fat (cm3) * 500 Omental 250 +115% Dog 4 SubQ Figure A12. Week 0 Week 6

FFA Visceral Fat Resistant Liver PEPCK G6Pase SREBP1 FABP TNF- IL-6 Leptin Adiponectin PPAR SREBP-1 HSL LPL Slide 45 Changes in gene expression Figure A13.

β3-blockade Free Fatty Acids Figure A14. 0.4 0.3 0.2 0.1 0.4 0.3 0.2

FFA “Pulsatile Lipolysis” “Constitutive Lipolysis” GH TSH, PTH ANP Glucocorticoids “intrinsic” Figure A15.